Company: TXG
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001770787-25-000032
Chunk: 9

Company: 10x Genomics, Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 1
Chunk 9
---
 revenue in the next 12 months, with the 

11

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

remainder thereafter. The contract liabilities of $33.5 million and $24.1 million as of March 31, 2025 and 2024, respectively, consisted of deferred revenue related to extended warranty service agreements.The following revenue recognized for the periods indicated were included in deferred revenue as of December 31, 2024 and 2023, respectively (in thousands):Three Months EndedMarch 31,20252024Deferred revenue recognized$5,857 $3,595 The following table represents revenue by source for the periods indicated (in thousands). Spatial products include the Company’s Visium and Xenium products:Three Months EndedMarch 31,20252024InstrumentsChromium$5,913 $7,850 Spatial8,902 17,603 Total instruments revenue14,815 25,453 ConsumablesChromium84,109 83,927 Spatial31,247 26,408 Total consumables revenue115,356 110,335 Services7,652 5,217 Products and services revenue137,823 141,005 License and royalty revenue17,060 1 Total revenue$154,883 $141,006 The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):Three Months EndedMarch 31,20252024AmericasUnited States(1)$86,818 $75,637 Americas (excluding United States)3,752 3,993 Total Americas90,570 79,630 Europe, Middle East and Africa31,895 34,721 Asia-PacificChina16,883 13,924 Asia-Pacific (excluding China)15,535 12,731 Total Asia-Pacific32,418 26,655 Total revenue$154,883 $141,006 (1) Includes license and royalty revenue.   

12

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

License and Royalty RevenueDuring the three months ended March 31, 2025, the Company settled its worldwide patent litigation with Vizgen, Inc. As part of that settlement, Vizgen has limited rights to certain intellectual property owned or exclusively licensed by the Company. As one part of the